Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 3/20 | 0.61 |
| ▸ | MAOB | P27338 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10584239 | 0.92 | MEN1 (0.61) | MEN1KMT2ARAB9AALDH1A1NPC1 | |
| SCHEMBL83796 | 0.85 | MEN1 (0.80) | MEN1KMT2ARAB9AALDH1A1NPC1 | |
| SCHEMBL8745139 | 0.85 | MAOB (0.44) | MEN1KMT2ARAB9AALDH1A1NPC1 | |
| Hydrochloric Acid SCHEMBL27352810 | 0.83 | MEN1 (0.77) | MEN1KMT2ARAB9AALDH1A1NPC1 | |
| SCHEMBL21333874 | 0.81 | IDO1 (0.43) | MEN1KMT2ARAB9AALDH1A1NPC1 | |
| SCHEMBL694407 | 0.79 | CYP1A2 (0.46) | MEN1KMT2ARAB9AALDH1A1NPC1 | |
| SCHEMBL4456394 | 0.79 | MEN1 (0.66) | MEN1KMT2ARAB9AALDH1A1NPC1 | |
| SCHEMBL402875 | 0.79 | MAOA (0.58) | MEN1KMT2ARAB9AALDH1A1NPC1 | |
| SCHEMBL694551 | 0.78 | DAO (0.50) | MEN1KMT2AALDH1A1MAOBLMNA | |
| SCHEMBL7779170 | 0.76 | MEN1 (0.67) | MEN1KMT2ARAB9AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2021-04-01 | — | — | US | claimed |
| EP-3763728-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) | 2021-01-13 | — | — | EP | claimed |
| WO-2019170046-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海来益生物药物研究开发中心有限责任公司 | 2019-09-12 | — | — | WO | claimed |
| US-8741887-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-03 | — | — | US | claimed |
| US-20130123232-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-05-16 | — | — | US | claimed |
| US-8367653-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-05 | — | — | US | claimed |
| US-8362000-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | claimed |
| EP-2421851-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| EP-2421847-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | claimed |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| WO-2010124102-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-7371747-B2 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-05-13 | — | — | US | claimed |
| EP-1446115-B1 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | claimed |
| EP-1446115-A4 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-02-02 | — | — | EP | claimed |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-01-20 | — | — | US | claimed |
| EP-1446115-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-08-18 | — | — | EP | claimed |
| WO-2003041649-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-05-22 | — | — | WO | claimed |
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| CN-108409837-B | Glycopeptide compound with anti-drug resistance bacterial activity, preparation method and application thereof | 上海来益生物药物研究开发中心有限责任公司 | 2021-09-24 | — | — | CN | disclosed |
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2021-04-01 | — | — | US | disclosed |
| EP-3763728-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019170046-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海来益生物药物研究开发中心有限责任公司 | 2019-09-12 | — | — | WO | disclosed |
| US-8741887-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-06-03 | — | — | US | disclosed |
| US-8623858-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20130123232-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123233-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-05-16 | — | — | US | disclosed |
| US-8367653-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8362000-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | disclosed |
| EP-2421847-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| EP-2421851-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | disclosed |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124102-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| US-7371747-B2 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-05-13 | — | — | US | disclosed |
| EP-1446115-B1 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | disclosed |
| EP-1446115-A4 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-02-02 | — | — | EP | disclosed |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-01-20 | — | — | US | disclosed |
| EP-1446115-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003041649-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-05-22 | — | — | WO | disclosed |
| EP-0534257-B1 | Salicylic acid derivatives, the process for preparing the same and the heat-sensitive recording materials comprising thereof | MITSUI TOATSU CHEMICALS (JP) | 1997-03-12 | — | — | EP | disclosed |
| EP-0524419-B1 | Heat-sensitive recording materials and phenol compounds | MITSUI TOATSU CHEMICALS (JP) | 1995-09-06 | — | — | EP | disclosed |
| US-5391806-A | A storage stable chromogens as color-developing agent or stabilizers | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-02-21 | — | — | US | disclosed |
| US-5306688-A | Color-forming, electron donating compound and electron accepting compound; storage stability of uncolored portion | MITSUI TOATSU CHEMICALS, INC. (JP) | 1994-04-26 | — | — | US | disclosed |
| US-5270281-A | Chromogenic compound | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0534257-A1 | Salicylic acid derivatives, the process for preparing the same and the heat-sensitive recording materials comprising thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-03-31 | — | — | EP | disclosed |
| EP-0524419-A1 | Heat-sensitive recording materials and phenol compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-01-27 | — | — | EP | disclosed |
| EP-0524419-A1 | Heat-sensitive recording materials and phenol compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MEN1 1953/4885KMT2A 1573/4885RAB9A 851/4885 |
| US-20100324013-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MEN1 1953/4885KMT2A 1573/4885RAB9A 851/4885 |
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | VIP, CUTA, MGAM | MEN1 3260/4885KMT2A 4167/4885RAB9A 1979/4885 |
| US-20130123233-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MEN1 1953/4885KMT2A 1573/4885RAB9A 851/4885 |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | CTSB, CTSK, CTSS | MEN1 4489/4885KMT2A 3522/4885RAB9A 1166/4885 |
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | VIP, CUTA, MGAM | MEN1 3260/4885KMT2A 4167/4885RAB9A 1979/4885 |
| US-20130123232-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MEN1 1953/4885KMT2A 1573/4885RAB9A 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.